Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
86%(6 trials)

Phase Distribution

Ph phase_3
5
71%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 3Large-scale testing
5(71.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 35 (71.4%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_1

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

NCT06954493
completedphase_3

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992
completedphase_3

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

NCT05399641
completedphase_1

ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects

NCT05668429
completedphase_3

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

NCT04029116
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06954493Phase 1

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

Completed
NCT03059992Phase 3

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Completed
NCT05399641Phase 3

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Completed
NCT05668429Phase 1

ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects

Completed
NCT04029116Phase 3

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Completed
NCT03734991Phase 3

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Completed
NCT03987620Phase 3

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7